Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis

被引：0
|
作者：
Tribich, Samuel
Maurice, James
机构：
来源：
FRONTLINE GASTROENTEROLOGY | 2020年 / 11卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [1] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [2] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Biemans, Vince B. C.
    Hoentjen, Frank
    Pierik, Marieke J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 92
  • [3] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis REPLY
    Sands, Bruce E.
    Schreiber, Stefan
    Lirio, Richard A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 93 - 94
  • [4] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Feagan, Brian G.
    Schreiber, Stefan
    Wolf, Douglas C.
    Axler, Jeffrey L.
    Kaviya, Arpeat
    James, Alexandra
    Curtis, Rebecca I.
    Geransar, Parnia
    Stallmach, Andreas
    Ehehalt, Robert
    Bokemeyer, Bernd
    Khalid, Javaria Mona
    O'Byrne, Sharon
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (06) : 1028 - 1035
  • [5] Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
    Yokomizo, Lauren
    Limketkai, Berkeley
    Park, K. T.
    BMJ OPEN GASTROENTEROLOGY, 2016, 3 (01):
  • [6] COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND
    Sruamsiri, R.
    VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [7] Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
    Fischer, A.
    Oppe, M.
    Stypa, S.
    Lukyanov, V.
    Petrakis, I.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S387 - S387
  • [8] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [9] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Warner, Ben
    Harris, Adam W.
    GASTROENTEROLOGY, 2012, 143 (01) : E42 - E42
  • [10] Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis
    Sandborn, William
    Van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas
    Kron, Martina
    Tighe, Mary
    Lazar, Andreas
    Thakkar, Roopal
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S3 - S4
12345